Kiromic BioPharma, Inc. (KRBP)

0.3600 -0.1240 (-25.62%) At close: 04:00PM EDT

Kiromic BioPharma, Inc.

7707 Fannin
Suite 140
Houston, TX 77054
United States
832 968 4888
https://www.kiromic.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 59

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pietro Bersani CPA, J.D.	CEO & Director	167.76k	N/A	1968
Dr. Scott Dahlbeck M.D., Pharm.D., PharmD	Chief of Staff	442.12k	N/A	1962
Mr. Daniel Clark	Chief Financial Officer	N/A	N/A	1989
Dr. David M. Spencer	Chief Scientific Officer	N/A	N/A	1962
Dr. Michael Ryan Ph.D.	Chief Bioinformatics Officer	N/A	N/A	1967

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiromic BioPharma, Inc., an artificial intelligence driven, end-to-end allogenic cell therapy company, develops multi-indication allogeneic T cell therapies for solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Corporate governance

Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.